Physicians currently rely on medical imaging to detect tumors in patients and monitor those in remission, but this method has limitations and a patient’s cancer can go unnoticed until it has already metastasized. To tackle this, Shervin, who is a radiation oncologist at Massachusetts General Hospital, will leverage his BroadIgnite funding to build tools that can detect microscopic levels of tumor DNA in patient blood samples for early, non-invasive cancer diagnosis.